Targeted Oncology interviews feature the world's leading oncologists sharing their insights on the latest news and advances in diagnostic testing, biomarkers, pathways, immunotherapy, and targeted therapeutics for better application into clinical practice.

CAR T-Cell Therapy Shows Consistent Safety and Pharmacokinetics in NHL

April 12, 2021

Scott R. Solomon, MD, discusses the adverse events and pharmacokinetics of lisocabtagene maraleucel in 12 patients with relapsed/refractory large B-cell non-Hodgkin lymphoma who had previously received anti-CD19 therapy.

Previous Trials Inform Toxicity Profile of Cabozantinib/Atezolizumab in mCRPC

March 18, 2021

Neeraj Agarwal, MD, discusses the possible adverse events of the randomized phase 3 CONTACT-02 trial of cabozantinib plus atezolizumab versus a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer.